PHAT Q4 2024 Earnings — Phathom Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

PHATPhathom Pharmaceuticals, Inc.

$891M

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$30M+4249.6% YoY

Gross Profit

$26M87.1% margin

Operating Income

-$59M-200.3% margin

Net Income

-$74M-251.0% margin

EPS (Diluted)

$-1.05

QoQ Revenue Growth

+81.4%

Cash Flow

Operating Cash Flow

-$63M

Free Cash Flow

-$63M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$378M

Total Liabilities

$632M

Stockholders' Equity

-$254M

Cash & Equivalents

$297M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$30M	$682,000	+4249.6%
Gross Profit	$26M	$330,000	+7733.0%
Operating Income	-$59M	-$70M	+15.0%
Net Income	-$74M	-$80M	+6.4%